Wiskott-Aldrich Syndrome Clinical Trial
Official title:
A Single Arm, Open-label Clinical Trial of Hematopoietic Stem Cell Gene Therapy With Cryopreserved Autologous CD34+ Cells Transduced With Lentiviral Vector Encoding WAS cDNA in Subjects With Wiskott-Aldrich Syndrome (WAS)
Verified date | March 2023 |
Source | Fondazione Telethon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103 Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene encoding for the Wiskott-Aldrich Syndrome is introduced by means of a third generation lentiviral vector.
Status | Active, not recruiting |
Enrollment | 10 |
Est. completion date | September 2027 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 65 Years |
Eligibility | Inclusion Criteria: - Age: up to 65 years - Diagnosis of WAS defined by genetic mutation and at least one of the following criteria: - Severe Wiskott-Aldrich Syndrome (WAS) gene mutation, defined by literature data (genotype/phenotype studies).; - Absent WASP expression, assessed by flow cytometry; - Severe clinical score (Zhu clinical score = 3); - No human leukocyte antigen (HLA)-identical related donor available for hematopoietic stem cells transplant (HSCT). Exclusion Criteria: - End-organ dysfunction, severe active infection not responsive to treatment or other severe disease or clinical condition which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. - Malignant neoplasia (except local skin cancer) or a documented history of hereditary cancer syndrome. - Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome and acute myeloid leukaemia , or other serious haematological disorders - Documented human immunodeficiency virus (HIV) infection - Prior allogeneic hematopoietic stem cell transplantation, with evidence of residual cells of donor origin - Symptomatic herpes zoster, not responsive to specific treatment - Evidence of acute tuberculosis - Acute or chronic stable Hepatitis B - Presence of positive Hepatitis C RNA test result at screening - Patients not eligible for mobilization protocols in order to obtain CD34+ cells - Previous Gene Therapy |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET) | Milan | |
United States | Children's Healthcare of Atlanta, Inc | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Fondazione Telethon | Ospedale San Raffaele |
United States, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Annualized rate of severe infections from 6 to 18 months after gene therapy compared with 1 year before gene therapy | 18 months | ||
Primary | Annualized rate of moderate and severe bleeding episodes up to 1 year after gene therapy compared with 1 year before gene therapy | 12 months | ||
Secondary | Evaluation of the overall survival | 36 months | ||
Secondary | Number of patients with Vector copy number (VCN)/cell > 0.1 measured in peripheral blood-derived CD3+ cells | 2 years | ||
Secondary | Percentage of WAS protein expression increased from pre-treatment levels in lymphocytes | 2 years | ||
Secondary | Percentage of WAS protein expression increased from pre-treatment levels in platelets | 2 years | ||
Secondary | Number of participants with successful engraftment of OTL-103 | Engraftment of of OTL-103 is measured by hematological reconstitution of an absolute neutrophil count > 500 cell/ul | 6 months | |
Secondary | The number of subjects presenting with malignancies or abnormal clonal proliferation | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
Completed |
NCT01953016 -
Participation in a Research Registry for Immune Disorders
|
||
Active, not recruiting |
NCT02333760 -
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
|
Phase 1/Phase 2 | |
Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Recruiting |
NCT04371939 -
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
|
Phase 2 | |
Completed |
NCT01347346 -
Gene Therapy for WAS
|
Phase 1/Phase 2 | |
Completed |
NCT00160355 -
Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome
|
Phase 1 | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Completed |
NCT01347242 -
Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
|
Phase 1/Phase 2 | |
Completed |
NCT01289847 -
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
|
Phase 4 | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Enrolling by invitation |
NCT03198195 -
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
|
N/A | |
Recruiting |
NCT03019809 -
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
|
Phase 2 | |
Terminated |
NCT00909363 -
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
|
Phase 2 | |
Enrolling by invitation |
NCT01852370 -
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
|
Phase 1/Phase 2 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01410825 -
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00004341 -
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
|
N/A | |
Completed |
NCT03399461 -
Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
|